End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
500.8 INR | +0.58% | -0.69% | -5.03% |
Jun. 03 | Tarsons Products Limited Announces Change of Name of Whole-Time Directors | CI |
May. 31 | Transcript : Tarsons Products Limited, Q4 2024 Earnings Call, May 31, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 58% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- With an expected P/E ratio at 42.35 and 45.53 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.03% | 320M | B- | ||
-6.66% | 12.28B | B+ | ||
+90.81% | 8.54B | C | ||
-22.14% | 6.58B | B- | ||
+8.86% | 5.77B | B | ||
-23.82% | 3.48B | C | ||
+5.12% | 2.54B | - | - | |
+43.10% | 2.41B | C | ||
-7.24% | 2.3B | B- | ||
-64.26% | 2.07B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TARSONS Stock
- Ratings Tarsons Products Limited